Last edition
News about "Aramchol therapeutics"
Tissue Dynamics and Galmed Pharmaceuticals partner to develop a human-centered cardiac fibrosis platform that will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.
Aramchol Therapeutics | 07/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members